ValuEngine upgraded shares of Athersys, Inc. (NASDAQ:ATHX) from a sell rating to a hold rating in a research report sent to investors on Wednesday.
A number of other research analysts have also recently issued reports on the company. Zacks Investment Research cut Athersys from a buy rating to a hold rating in a research note on Thursday, August 31st. Maxim Group set a $12.00 price objective on Athersys and gave the company a buy rating in a research note on Monday, August 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $7.17.
Athersys (ATHX) opened at $2.05 on Wednesday. Athersys has a 12 month low of $1.02 and a 12 month high of $2.63.
Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of Athersys by 4.8% during the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares during the period. Bank of America Corp DE boosted its holdings in shares of Athersys by 17.2% during the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 9,019 shares during the period. Thompson Davis & CO. Inc. boosted its holdings in shares of Athersys by 743.9% during the third quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 56,683 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Athersys by 329.7% during the second quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 56,345 shares during the period. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Athersys during the second quarter worth about $113,000. Institutional investors own 19.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Athersys, Inc. (ATHX) Upgraded at ValuEngine” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/25/athersys-inc-athx-upgraded-at-valuengine.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.